eStudySite provides sponsors and CROs with advanced clinical trials research sites. Through contracts with the company's Hospital Partners, the company rapidly enrolls large numbers of qualified study subjects and deploy an elite core of critical care and research professionals to each study. Sponsors and CROs experience accelerated approval timelines.On November 11, 2020 eStudySite was acquired by Velocity Clinical Research. The terms of the transaction were not disclosed.
Missing: eStudySite's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: eStudySite's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing eStudySite
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
eStudySite is included in 2 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Latest eStudySite News
Nov 11, 2020
News provided by Share this article DURHAM, North Carolina, Nov. 11, 2020 /PRNewswire/ -- North Carolina-based clinical research site company, Velocity Clinical Research, today announces the acquisition of eStudySite Inc, adding two sites in San Diego, California to its North American site portfolio, bringing the total to 14. The La Mesa and Chula Vista sites will make significant contributions to Velocity's drive to recruit more volunteers from minority communities. The acquisition comes amid Velocity's participation in COVID studies where it is seeking to recruit over 20,000 volunteers across 10 of its existing sites. The acquisition also expands Velocity's testing capabilities in preventative treatments. The new sites in La Mesa and Chula Vista are enrolling patients for both COVID-19 treatment and COVID-19 vaccine trials. Dr Paul Evans, CEO and President of Velocity Clinical Research, said: "Velocity has been aggressively expanding both its site portfolio and therapeutic ability since we launched three years ago. This acquisition is strategic for two reasons. Firstly, these sites are important for recruiting volunteers from minority communities and secondly, we anticipate a resurgence in the infectious disease area. "2020 has been an unprecedented year for the clinical trials business and finding a coronavirus vaccine will probably be the most important work of our lives. But the industry has a problem when it comes to recruiting volunteers from minority communities and so they are severely underrepresented in clinical trial data. This problem has been magnified in the race to find a COVID vaccine. It will take myriad solutions to ensure people from these communities feel comfortable volunteering in clinical research and one step is having more accessible clinics." The acquisition enhances and adds new therapeutic capabilities to Velocity's repertoire, including infectious and orphan diseases. eSS's hospital affiliation Sharp HealthCare at each of its sites, also provides them access to expanded patient populations and the ability to perform hospital-based and confinement studies. Dave McCarthy, CEO of eStudysite, commented "We believe that Velocity has the right people and experience to help evolve the clinical trial landscape and that's why we are delighted to become part of the group. eSS shares Velocity's vision of providing the infrastructure to speed up and standardise data collection during trials in order that drugs and vaccines are approved quicker. Velocity Clinical Research is currently enrolling patients in COVID-19 studies including all of the Operation Warp Speed studies across 10 sites in the US, in Ohio, Florida, California, Texas, Rhode Island, Utah, Idaho and Oregon. Dr Evans added, "This year has tangibly demonstrated the benefit that prevention treatments like vaccines for infectious disease can have. We expect more funding in this area as a result and subsequently, more clinical testing. "Today's acquisition demonstrates Velocity's commitment to advancing the clinical trials industry and we are actively looking to add more sites and therapeutic areas to our growing footprint in the US." Notes to editors People who wish to volunteer for a COVID study conducted by Velocity can register their interest at www.velocityclinicalresearch.com eStudySite Inc. primary areas of therapeutic indication coverage: Infectious Disease Banning, California About Velocity Clinical Research Velocity Clinical Research, headquartered in Durham, N.C, is a leading site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. The company has 14 sites across the United States. With over 35 years of experience and more than 4500 studies completed, Velocity sites have refined their patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality, placing the care of the patient at the heart of everything they do. For more information visit our website at https://velocityclinical.com . SOURCE Velocity Clinical Research
eStudySite Frequently Asked Questions (FAQ)
When was eStudySite founded?
eStudySite was founded in 1999.
Where is eStudySite's headquarters?
eStudySite's headquarters is located at 292 Euclid Avenue, San Diego.
What is eStudySite's latest funding round?
eStudySite's latest funding round is Acquired.
How much did eStudySite raise?
eStudySite raised a total of $6M.
Who are the investors of eStudySite?
Investors of eStudySite include Velocity Clinical Research, Ticonderoga Capital and Celerity Partners.
Who are eStudySite's competitors?
Competitors of eStudySite include Avalere Health, Shearwater Health, Path-Tec, Draper Laboratory, deCODE genetics and 11 more.
Compare eStudySite to Competitors
The company provide clinical research services to area physicians in a range of therapeutic specialties and contract with pharmaceutical companies and contract research organizations (CROs) to conduct in-patient clinical research. The company have successfully conducted more than 500 Phase I, II, III, and IV clinical trials and utilize the Clinasyst Software System for trial management with a database of greater than 40,000 subjects.
CROM Srl is Research Organisation for Medical and Pharmaceutical Projects. They provide services such as: Clinical Trials Monitoring, Data Management and Statistics, Medical Services and Communication, Outcome Research, Pharmacoeconomics, Q o L, Megatrials Experience, Meeting and Seminars and Internet and Medical Projects. nnnn
PercipEnz Technologies, Inc., founded in 2000 and headquartered in Madison, Wisconsin, aims to develop and markets , enterprise-class clinical and translational research management systems for academic research organizations.
Micromyx is a microbiology services company engaged in anti-infective discovery and development for the pharmaceutical, biotechnology, and animal health industries. Founded in 2004 by former pharmaceutical industry infectious disease scientists, Micromyx is a contract research organization that aims to offer clients documented, top-of-the-line laboratory services from experts who have successfully gained FDA approval of new antibiotics.
NCI Cancer Hospital is a private oncology centre in Malaysia that combines treatment and clinical research. NCI aims to provide a range of services from diagnosis, laboratory analysis, surgery, chemotherapy and radiotherapy. It operates to GCP and has conducted clinical trials for a number of pharmaceutical companies including Roche, BMS and AstraZeneca.
CRO stands for Contract Research Organization, which takes part in clinical trial operations conducted by pharmaceutical companies or other entities. The company at TMRC Co., Ltd. provide monitoring, data management and other related operations engaged in cancers, to major pharmaceutical companies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.